A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan
Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines.
Over 75 years of history
More than 10,000 employees worldwide
¥ 600.1 billion annual revenue (FY2017)
Eisai’s Global Network
More than 40 subsidiaries worldwide
15 Drug Discovery, Research and Development, and Clinical Research Sites
10 Production sites
Eisai’s Therapeutic Areas of Focus : Neurology and Oncology
Eisai has positioned neurology and oncology as its therapeutic areas of focus, where there are many diseases for which adequate treatments have yet to be established. In order to fulfill patients’ unmet needs, Eisai sets out a goal to be a “Medico Societal Innovator” or in other words, “a company that changes society through creating medicines and providing solutions” in its medium-term business plan “EWAY 2025”.
Eisai’s Vision for 2025 : To be a “Medico Societal Innovator”
Creation of Innovative Medicines
to fulfill unmet medical needs
to improve efficiency and productivity
Provision of Solutions
to address gaps in infrastructure
Flexible Pricing Policies
to reduce financial barriers to treatment
to deliver products to people who need them
We give first thought to patients and their families, and to increasing the benefits health care provides.
Eisai's corporate philosophy reflects our commitment to business activities aiming to increase the benefits to patients, their families, and consumers, who we clearly recognize as the key players in healthcare. This corporate philosophy is summarized by the term
“human health care (hhc)”.
All employees are recommended to spend 1% of
their working hours with patients
Eisai’s Access to Medicines Initiatives
“Access to Medicines” is about ensuring that medicines and treatments are made available to the communities that need them. Eisai is promoting initiatives for improving access to medicines in developing and emerging countries.
1.59 billion DEC tablets
(As of December 2018)
Eisai is committed to supplying tablets free of charge from its Vizag Plant in India to 250 million people at risk in lymphatic filariasis endemic countries through the World Health Organization until the disease is completely eliminated in these countries.